Senile lymphoma
Conditions
Interventions
Case series:The first cycle of chemotherapy, subcutaneous injection of pegfilgrasim 24-72 hours after the end of chemotherapy
Sponsors
Sun Yat-sen University Cancer Hospital
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Aged = 65 years male and female; (2) Patients with lymphoma diagnosed by histopathology or cytology; (3) Patients requiring multi-cycle chemotherapy; (4) Planned chemotherapy regimen FN risk = 20 %, or 10% <FN risk < 20% with high risk factors for at least one FN ; (5) Physical status (KPS) score = 70 points; (6) The expected survival time is more than 3 months; (7) The bone marrow hematopoietic function is normal (ANC =1.5×10^9/L, PLT=100×10^9/L, Hb=80g/L, WBC=3.0×10^9/L); (8) Subjects (or their legal representatives/guardians) must sign an informed consent form.
Exclusion criteria
Exclusion criteria: (1) lymphoma central involvement; (2) those who have undergone hematopoietic stem cell transplantation or organ transplantation; (3) local or systemic infections that are not adequately controlled; (4) severe visceral dysfunction and have occurred in the last 6 months Myocardial infarction; (5) liver function tests total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST) are > 2.5 times the upper limit of normal, if due to liver metastasis, the above indicators > 5 times Upper limit of normal value; renal function test: serum creatinine (Cr) > 2 times normal upper limit; (6) allergic to PEG-rhG-CSF, rhG-CSF and other preparations or proteins expressed by Escherichia coli; (7) Severe mental illness affects informed consent and/or adverse reaction presentation or observation; (8) The investigator judges patients who are not suitable for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of neutropenic fever (FN) in each cycle of chemotherapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of IV degree ANC reduction in each chemotherapy cycle;Incidence of dose adjustment of chemotherapy drugs in each chemotherapy cycle;Incidence of chemotherapy delays in each chemotherapy cycle;Proportion of patients receiving antibiotics during the entire chemotherapy period;Occurrence and severity of adverse reactions; | — |
Countries
China
Contacts
Public ContactHuiqiang Huang
Sun Yat-sen University Cancer Hospital
Outcome results
None listed